Candela News
19 articles
/PRNewswire/ -- Sapiens International Corporation (NASDAQ: SPNS) (TASE: SPNS), a global leader in intelligent insurance software solutions today announced the...
Sapiens International Corporation, a leader in intelligent insurance software solutions, has announced the acquisition of Candela, an intelligent automation company serving insurance clients in the APAC region. This strategic acquisition aims to enhance Sapiens life product portfolio and expand its presence in the APAC market. Candela, currently part of Azentio, offers an end-to-end insurance automation platform and has 23 customers across several countries. The acquisition, valued at $22 million, is expected to close in the second quarter of 2025 and will be accretive to profit starting from the fourth quarter of 2025. This move is expected to strengthen Sapiens position globally and enhance its insurance platform offerings.
AcquisitionCustomersPartners
Aesthetic device maker Candela Medical postpones $250 million IPO
Candela Medical, a company that makes energy-based medical devices for aesthetic procedures, has postponed its IPO. The company had planned to raise $250 million through the offering of 14.7 million shares. Candela Medical, founded in 2010, reported $390 million in sales for the 12 months ended June 30, 2021. The IPO was set to list on the Nasdaq under the symbol CDLA, with BofA Securities, Goldman Sachs, Barclays, Baird, Canaccord Genuity, and Stifel as joint bookrunners.
Public Trading
4 שנים לאחר שנמחקה: אייפקס מחזירה את סינרון-קנדלה לנאסד"ק
Candela, a medical aesthetics company, has released a prospectus for its IPO on NASDAQ. The company was created from a merger between Israeli company Syneron and American company Candela, which Syneron acquired in 2009 for $65 million in a stock deal. In 2017, Apex Private Equity acquired the merged company for $397 million and delisted it from NASDAQ. Now, it is being reissued. The companys valuation for the IPO has not been disclosed, but it is likely higher than when it was acquired. Candela recorded revenues of $209 million in the first half of 2021, an almost 50% increase compared to the same period last year.
Public TradingManagement Changes
Candela announces the launch of the Frax Pro™ system, the smart way to Frax
Candela announces the availability of the Frax Pro system, a dual-depth skin resurfacing device that stimulates growth of new collagen. The system features both Frax 1550 and Frax 1940 applicators, targeting different skin layers. Clinical studies show high rates of textural improvement and patient satisfaction. The Frax Pro system removes limitations of earlier fractional laser systems and offers a high return on investment. The system is interchangeable with the Nordlys platform, making it the first to provide dual fractional wavelengths. Candela is a leading global medical aesthetic device company with a wide product portfolio and global distribution.
CustomersPartners
Merz Aesthetics and Candela Corporation Launch Commercial Collaboration
Merz Aesthetics and Candela Medical are collaborating to expand their product portfolios and meet patient demand for aesthetic care. The collaboration will provide customers with a comprehensive portfolio of high-quality aesthetic products and streamlined purchasing options. Merz Aesthetics will gain access to Candelas leading aesthetic device portfolio, while Candela will offer injectables and topicals to its customer base. The collaboration aims to deliver clinical value to aesthetic practices and enhance customer service and training. The partnership will start in North America and plans to expand globally.
CustomersPartners
Candela Announces Health Canada Approval Of Two New Gynecological Indications For CO2RE® Laser Platform
Candela Corporation has received approval from Health Canada for the use of its CO2RE laser in the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) in adult women. The CO2RE laser offers a nonsurgical, hormone-free alternative for women experiencing symptoms associated with GSM and SUI. The approval is based on extensive clinical research and studies that have shown significant improvements in vaginal health and urinary incontinence severity after treatment with the CO2RE laser. Candela Corporation is a leading global aesthetic device company that provides energy-based solutions for various medical aesthetic applications. The approval of the CO2RE laser for these indications demonstrates the companys commitment to womens health and expands its product portfolio.
Customers
Candela® And MT.DERM Sign Exclusive Collaboration Agreement
Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERMs medical microneedling products. Candela will commercialize the Exceed™ medical microneedling system globally, with a first launch in the United States. The agreement may be expanded with additional products in the future. The collaboration strengthens Candelas product portfolio and positions the company for expanded market penetration.
Partners
Candela and InMode Announce Settlement Of Patent Infringement Lawsuit
Syneron Medical Ltd. and Candela Corporation have entered into a worldwide comprehensive mutual settlement agreement, ending the patent disputes between the companies. The settlement allows InMode to continue marketing its bi-polar fractional RF product line, protecting Candelas investment in the development of long pulse category products. Candelas Profound system and InModes Fractora and Morpheus8 are FDA-cleared for various skin treatments. The settlement terms were not disclosed.
Partners
Syneron-Candela Is Now Candela
Syneron-Candela has rebranded the company to Candela and unveiled its new corporate branding. The rebranding is designed to support continued global market growth as a unified single entity. The companys new corporate identity reflects the unification of the Syneron and Candela brands and emphasizes its commitment to safety, efficacy, and reliability. The rebrand includes a new corporate website, marketing materials, and campaigns. The company aims to strengthen its partnerships with physicians and medical aesthetic practices globally.
Partners
Syneron Candela Announces Updates In Patent Infringement Cases
Syneron Candela, a global aesthetic device company, has announced updates to several patent infringement lawsuits. The company has filed complaints against 18 manufacturers and distributors of fractional RF micro-needle dermatological treatment systems. The lawsuits seek to block importation of these products into the US. In addition, a separate patent infringement lawsuit concerning Sublative technology has resulted in the asserted claims being held invalid. Syneron Candela has filed an appeal in this case. The company emphasizes its commitment to protecting its technology and the trust of its physician partners. Syneron Candela offers a wide range of medical-aesthetic applications and has a global commercial footprint.
CustomersPartners
Syneron Candela Announces Launch of Direct Operation in Korea
Syneron Candela has announced the opening of a new headquarters in Korea to support all commercial activities for its portfolio of products. The company aims to provide direct support to its customers in Korea, addressing their capital needs and offering high levels of service, technical support, education, training, and clinical support. This move reflects Syneron Candelas vision to be the leading aesthetic medical device company and its commitment to providing the highest level of customer support worldwide. The company expects strong growth in Korea and expresses gratitude to its past distribution partner, ShinHan. The opening of the new headquarters is seen as a sign of Syneron Candelas commitment to the medical practices in Korea and their patients.
Customers
Syneron Candela Announces Acquisition Of Ellipse
Syneron Candela wins FDA nod for Vbeam Prima cosmetic laser
Syneron Candela has received FDA clearance for its next-gen Vbeam Prima cosmetic laser, designed to treat various skin conditions. The device offers advanced features to improve results and treatment experience. The companys CEO, Geoffrey Crouse, stated that the FDA clearance represents a step forward in the treatment of vascular and pigmented skin conditions. Syneron Candela was acquired by private equity fund Apax Partners for approximately $400 million in July. The company aims to recommit to scientific leadership, clinical results, and long-term partnerships with customers.
CustomersAcquisition
Syneron Candela Completes Previously Announced Transaction with Funds Advised by Apax Partners and Becomes a Private Company
Syneron Medical Ltd. has been acquired by an affiliate of funds advised by Apax Partners for $11.00 per share in cash, in a transaction valued at approximately $400 million. As a result of the acquisition, Syneron Candela is now a privately held company. The companys ordinary shares will be delisted from The Nasdaq Stock Market. Geoffrey Crouse has been appointed as the Chief Executive Officer and a member of the Board of Directors of Syneron Candela. Other new members of the senior executive team include Mike Johnson as Chief Financial Officer, Mary Trout as President, Americas, and Todd Van Horn as Chief Business Officer. The newly appointed executives will be headquartered in the United States. Barclays acted as the exclusive financial advisor to Syneron Candela.
Acquisition
Syneron Candela Announces Shareholder Approval of Proposed Acquisition by Funds Advised by Apax Partners
Syneron Medical Ltd. has announced that its shareholders have approved the acquisition of Syneron Candela by an affiliate of funds advised by Apax Partners. The acquisition is valued at approximately $397 million and is expected to be completed in mid-July, subject to closing conditions. Syneron Candela is a leading global non-surgical aesthetic device company with a comprehensive product portfolio. The companys technology enables physicians to provide advanced solutions for various medical-aesthetic applications. Syneron Candela has a wide portfolio of trusted products and operates in nearly 100 countries.
Acquisition
Apax confirms Syneron acquisition for $397m
Israeli esthetic medical company Syneron Medical Ltd. is being acquired by private equity advisory firm Apax Partners for $397 million. The acquisition price represents a 15% premium on Syneron Candelas average closing price in the first quarter. The transaction is subject to customary closing conditions and has been unanimously approved by the Syneron Candela Board of Directors. The acquisition is seen as a positive outcome for shareholders and is expected to add significant value and expertise to Syneron Candelas growth strategy. Major Israeli institutional shareholders include Migdal Insurance and Financial Holdings Ltd., The Phoenix Holdings Ltd., Menorah Mivtachim Holdings Ltd., and Yelin Lapidot.
Acquisition
Apax buying Syneron for $400-500m
Israeli esthetic medical products company Syneron will be sold to private equity firm Apax Partners for $400-500 million. Synerons market cap is currently $366.2 million. The acquisition comes after Synerons two main Israeli competitors, Lumenis and Alma Lasers, were sold in the past few years.
Acquisition
Syneron Medical and Unilever Join Forces for "Iluminage Beauty" - Plastic Surgery Practice
Syneron Medical Ltd and Unilever Ventures are forming a joint venture called Iluminage Beauty. Unilever Ventures will invest $25 million and transfer its luxury beauty subsidiary Iluminage to the joint venture. Syneron Medical will also transfer its Syneron Beauty subsidiary and related home-use businesses to the joint venture. Unilever Ventures will hold 51% of Iluminage Beauty, and Syneron Medical will retain 49%. The transaction is expected to close before the end of the year.
Partners
בעלת מניות חדשה ויוקרתית בסינרון: פידליטי הגיעה לאחזקה של 5.6%
סינרון, a company that manufactures laser devices for cosmetic treatments, has reported a new significant shareholder, קרנות הנאמנות האמריקאית (Fidelity), which holds approximately 5.6% of the companys shares. The largest shareholders in סינרון are Shimon Eckhouse and Michael Karayandl, the founders of the competing company Lumens, each holding 9.3% of the company. The companys CEO, Moshe Mizrahi, holds about 5.4% of the company through an investment company. סינרון is traded on the NASDAQ with a market value of $760 million, which is 2.6 times the value at which the company was issued in August of last year. The stock price has dropped by about 30% since August, from $43 to $31.
InvestmentPublic Trading
